RxDoctor Payments Data

Enas Sallam, MD

Internal Medicine · Sarasota, FLNPI 1578553434

Payments from drug & device makers

$6,985in general payments, 2019–2025

Across 373 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$832
  • Novo Nordisk$830
  • Pfizer$818
  • Lilly USA, LLC$458
  • Amgen$430
  • GSK$337
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,87998%
  • Education$1062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,985 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$158,512
Medicare patients
492
Services billed
2,667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$33,390
JardianceEmpagliflozin11$18,275
MounjaroTirzepatide15$16,102
XareltoRivaroxaban11$13,037
JanuviaSitagliptin Phosphate13$12,228
PremarinEstrogens, Conjugated13$6,227
SynthroidLevothyroxine Sodium50$5,120
Rosuvastatin Calcium345$4,127
Estradiol58$4,060
YuvafemEstradiol16$3,513
Levothyroxine Sodium300$3,334
SingulairMontelukast Sodium12$3,011
Pantoprazole Sodium164$2,816
Ezetimibe57$2,578
ValacyclovirValacyclovir Hcl28$2,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$818$39,61646 claims
Boehringer IngelheimJardiance$54$18,27511 claims
Lilly USA, LLCMounjaro$458$16,10215 claims
Johnson & JohnsonXarelto$95$13,03711 claims
MerckJanuvia$297$12,22813 claims
AbbVieSynthroid$832$5,12050 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →